title: Salvage therapy for refractory rejection and persistence of donor-specific antibodies after intestinal transplantation using the proteasome inhibitor bortezomib.
authors.forename: Undine A
authors.initials: UA
authors.lastname: Gerlach
authors.forename: Constanze
authors.initials: C
authors.lastname: Schoenemann
authors.forename: Nils
authors.initials: N
authors.lastname: Lachmann
authors.forename: Martin
authors.initials: M
authors.lastname: Koch
authors.forename: Andreas
authors.initials: A
authors.lastname: Pascher
mesh_terms: D018951:Antigens, CD20 / Q000096:biosynthesis; D001854:Bone Marrow Cells / Q000166:cytology; D001897:Boronic Acids / Q000494:pharmacology*; D000069286:Bortezomib; D006084:Graft Rejection; D006801:Humans; D056724:Immunity, Humoral; D007422:Intestines / Q000637:transplantation; D008875:Middle Aged; D011480:Protease Inhibitors / Q000494:pharmacology*; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000494:pharmacology*; D016879:Salvage Therapy / Q000379:methods*; D012778:Short Bowel Syndrome / Q000628:therapy; D053668:Syndecan-1 / Q000096:biosynthesis; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D018951:Antigens, CD20; D001897:Boronic Acids; D011480:Protease Inhibitors; D061988:Proteasome Inhibitors; D011719:Pyrazines; D053668:Syndecan-1; D000069286:Bortezomib